BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.
benzinga_article
BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.
